NeuroCog Trials Appoints Health Care Banker, Josh Spiegel, CFA To Chief Operating Officer

DURHAM, N.C., July 20, 2015 /PRNewswire/ -- NeuroCog Trials announced today the appointment of a new Chief Operating Officer, Josh Spiegel.  In this newly restored position, Mr. Spiegel will assume the responsibility of strategic and operational growth for NeuroCog.

"While some pharmaceutical companies have been reducing their investment in CNS, we have been able to have substantial growth over the past few years," said Richard Keefe, PhD, Founder and Chief Executive Officer of NeuroCog Trials.  "We feel that hiring Mr. Spiegel heralds a new era for NeuroCog.  His experience in finance and market analysis will help us to continue our trajectory with a new level of sophistication and maturity.  We expect tremendous gains in our capacity to provide key services for increasingly larger trials across a broad range of CNS and other therapeutic areas."

Mr. Spiegel brings to the company more than 16 years of experience in investment banking and has worked for companies in many industries including healthcare, business services and technology.  Prior to joining NeuroCog Trials, he was a founding partner and Principal at Cypress Associates LLC, a New York based Investment Banking firm, where he was responsible for a broad range of transactions including mergers and acquisitions, restructurings, and equity offerings. Before joining Cypress, he was with CIBC World Markets contributing as an Investment Banking Analyst in the technology group.  Mr. Spiegel earned his B.A. in Economics and Public Policy Studies from Duke University and holds the Chartered Financial Analyst® designation.

About NeuroCog Trials

NeuroCog Trials Inc. is the leading cognition services company for the pharmaceutical industry.  For more than 10 years, NeuroCog Trials has provided  consulting, site screening, rater training and certification, and data review services to more than 85 clinical trials in over 25 countries.  NeuroCog Trials has certified more than 6,000 neurocognitive testers and assured data quality for over 100,000 assessments across a variety of therapeutic areas, including schizophrenia, Alzheimer's disease, major depressive disorder, bipolar disorder and brain cancer.  Our mission is to facilitate the development of novel therapies to enhance cognition.  We bring to all of our work deep expertise, strategic innovation, and an unwavering commitment to research excellence.

For more information on NeuroCog Trials, its services, and licensing inquiries for its exclusive neuropsychological and functional capacity assessment batteries, please see www.neurocogtrials.com.

Logo - http://photos.prnewswire.com/prnh/20150720/238213LOGO

SOURCE NeuroCog Trials

Related Links

http://www.neurocogtrials.com